Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $13,754.00 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,980 shares of the firm’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total transaction of $13,754.00. Following the completion of the sale, the chief technology officer now owns 1,836,704 shares in the company, valued at $4,224,419.20. This represents a 0.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

David Badawi also recently made the following trade(s):

• On Friday, January 17th, David Badawi sold 5,423 shares of Sight Sciences stock. The shares were sold at an average price of $2.78, for a total value of $15,075.94.
• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The shares were sold at an average price of $3.26, for a total value of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Trading Down 0.9 %

NASDAQ SGHT traded down $0.02 during mid-day trading on Thursday, reaching $2.23. 358,040 shares of the stock were exchanged, compared to its average volume of 208,670. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The stock has a market cap of $114.47 million, a P/E ratio of -2.19 and a beta of 2.52. The stock has a 50 day simple moving average of $2.68 and a 200-day simple moving average of $3.89. Sight Sciences, Inc. has a one year low of $2.05 and a one year high of $8.45.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The business had revenue of $19.07 million during the quarter, compared to the consensus estimate of $18.98 million. During the same period last year, the business posted ($0.22) earnings per share. On average, analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Sight Sciences

Several institutional investors have recently added to or reduced their stakes in the business. KCK LTD. bought a new stake in shares of Sight Sciences in the 4th quarter valued at $15,925,000. Barclays PLC boosted its stake in Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company’s stock worth $317,000 after acquiring an additional 38,248 shares in the last quarter. Geode Capital Management LLC grew its holdings in Sight Sciences by 1.6% in the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares during the period. State Street Corp increased its stake in Sight Sciences by 17.4% in the third quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after purchasing an additional 95,843 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in Sight Sciences by 46.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock valued at $1,310,000 after purchasing an additional 65,767 shares in the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SGHT has been the subject of several recent research reports. Piper Sandler lowered their price objective on Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Lake Street Capital reduced their target price on shares of Sight Sciences from $3.00 to $2.50 and set a “hold” rating on the stock in a report on Thursday, March 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research note on Thursday, March 6th. Stifel Nicolaus cut their price target on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Finally, UBS Group decreased their price objective on Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a report on Monday, January 27th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $3.83.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.